WO2008145681A3 - Ccr2 receptor antagonists and uses thereof - Google Patents

Ccr2 receptor antagonists and uses thereof Download PDF

Info

Publication number
WO2008145681A3
WO2008145681A3 PCT/EP2008/056573 EP2008056573W WO2008145681A3 WO 2008145681 A3 WO2008145681 A3 WO 2008145681A3 EP 2008056573 W EP2008056573 W EP 2008056573W WO 2008145681 A3 WO2008145681 A3 WO 2008145681A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
ccr2 receptor
ccr2
pulmonarydiseases
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/056573
Other languages
French (fr)
Other versions
WO2008145681A2 (en
Inventor
Heiner Ebel
Stefan Peters
Silke Hobbie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to JP2010509818A priority Critical patent/JP5603770B2/en
Priority to CA2687931A priority patent/CA2687931C/en
Priority to US12/602,274 priority patent/US8653262B2/en
Priority to EP08760165.4A priority patent/EP2155689B1/en
Publication of WO2008145681A2 publication Critical patent/WO2008145681A2/en
Publication of WO2008145681A3 publication Critical patent/WO2008145681A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonarydiseases like asthma and COPD.
PCT/EP2008/056573 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof Ceased WO2008145681A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2010509818A JP5603770B2 (en) 2007-05-31 2008-05-29 CCR2 receptor antagonist and use thereof
CA2687931A CA2687931C (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof
US12/602,274 US8653262B2 (en) 2007-05-31 2008-05-29 CCR2 receptor antagonists and uses thereof
EP08760165.4A EP2155689B1 (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109376 2007-05-31
EP07109376.9 2007-05-31

Publications (2)

Publication Number Publication Date
WO2008145681A2 WO2008145681A2 (en) 2008-12-04
WO2008145681A3 true WO2008145681A3 (en) 2009-03-05

Family

ID=38752546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/056573 Ceased WO2008145681A2 (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof

Country Status (8)

Country Link
US (1) US8653262B2 (en)
EP (1) EP2155689B1 (en)
JP (1) JP5603770B2 (en)
AR (1) AR066799A1 (en)
CA (1) CA2687931C (en)
CL (1) CL2008001593A1 (en)
TW (1) TW200904434A (en)
WO (1) WO2008145681A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028588T2 (en) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
DE102006039003A1 (en) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New connections
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2010017850A1 (en) * 2008-08-12 2010-02-18 Boehringer Ingelheim International Gmbh Process for preparing cycloalkyl-substituted piperazine compounds
EP2025675A1 (en) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides with analgetic activity
EP2188269B1 (en) 2007-08-14 2014-05-07 Boehringer Ingelheim International GmbH Aryl sulfonamides with analgesic activity
US20100331298A1 (en) * 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
CA2742306A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
ES2551557T3 (en) 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammations, asthma and COPD
BRPI1012108B8 (en) 2009-05-22 2021-05-25 Incyte Corp compound 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile, its composition, its uses and process for preparing a phosphoric acid salt
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PL2513093T3 (en) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp New CCR2 receptor antagonists and their application
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2011141474A1 (en) * 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
EA202091303A3 (en) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн JAK INHIBITOR COMPOSITION FOR LOCAL APPLICATION
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
JP5721242B2 (en) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel CCR2 antagonist
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
ES2536415T3 (en) 2010-11-19 2015-05-25 Incyte Corporation Pyrrolopyridines and heterocyclic substituted pyrrolopyrimidines as JAK inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN103649086A (en) * 2011-05-12 2014-03-19 生态学有限公司 Methods for preparing naphthyridines
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
JP5786258B2 (en) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel and selective CCR2 antagonist
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
TW201406761A (en) 2012-05-18 2014-02-16 Incyte Corp Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
KR102242077B1 (en) 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 Sustained-release dosage forms of ruxolitinib
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
WO2014169087A2 (en) * 2013-04-10 2014-10-16 The Trustees Of Columbia University In The City Of New York Treatment of proximal spinal muscular atrophy
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
MX376856B (en) 2013-08-07 2025-03-07 Incyte Holdings Corp EXTENDED-RELEASE DOSAGE FORMS FOR A JAK 1 (JANUS KINASE 1) INHIBITOR.
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EP3256126B1 (en) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
MX383744B (en) 2015-07-02 2025-03-14 Centrexion Therapeutics Corp (4-((3<i>R</i>,4<i>R</i>)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2<i>R</i>,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4YL)METHANONE CITRATE
CN112457255B (en) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 Compounds and their use for treating cancer
TW201924683A (en) 2017-12-08 2019-07-01 美商英塞特公司 Low dose combination therapy for treatment of myeloproliferative neoplasms
MD3746429T2 (en) 2018-01-30 2022-08-31 Incyte Corp Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
KR20260080448A (en) 2018-03-30 2026-06-02 인사이트 코포레이션 Treatment of hidradenitis suppurativa using jak inhibitors
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3218259A1 (en) * 2021-04-30 2022-11-03 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2023243601A1 (en) 2022-06-13 2023-12-21 モジュラス株式会社 Azacycloalkyl carbonyl cyclic amine compound

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032526A (en) * 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
WO1986006719A1 (en) * 1985-05-15 1986-11-20 Chemie Linz Aktiengesellschaft New pyridazine compositions, production process thereof and fungicides and algicides containing them
WO1999021834A1 (en) * 1997-10-27 1999-05-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
WO2003066604A2 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
WO2005009976A1 (en) * 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
US20050192302A1 (en) * 2003-12-18 2005-09-01 Chu-Biao Xue 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
WO2005084667A1 (en) * 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2006001958A2 (en) * 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
WO2006050389A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods
WO2007003604A2 (en) * 2005-07-04 2007-01-11 Novo Nordisk A/S Hists1mine h3 receptor antagonists
WO2007084868A2 (en) * 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426382A (en) 1980-02-13 1984-01-17 Sankyo Company Limited 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
ES8802151A1 (en) * 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Novel (4-substituted-piperazinyl)pyridazines.
AU678186B2 (en) * 1992-10-23 1997-05-22 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
JP3166376B2 (en) 1993-02-03 2001-05-14 松下電器産業株式会社 Heat utilization equipment
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) * 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JPH1190106A (en) * 1997-09-26 1999-04-06 Daicel Chem Ind Ltd Simulated moving bed type chromatographic separation device
EP1131318B1 (en) * 1998-11-20 2004-03-24 G.D. Searle LLC Process for making 5-substituted pyrazoles using dithietanes
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
EP1046593A1 (en) * 1999-04-12 2000-10-25 Heineken Technical Services B.V. Closure for container
SK286641B6 (en) 1999-05-04 2009-03-05 Schering Corporation Piperazine derivatives useful as CCR5 antagonists, pharmaceutical compositions comprising them and their use
DZ3347A1 (en) 2000-05-22 2001-11-29 Aventis Pharma Inc ARYLMETHYLAMINE DERIVATIVES FOR THEIR USE AS TRYPTASE INHIBITORS
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
HUP0200849A2 (en) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them
ES2306859T3 (en) * 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv DERIVATIVES OF SULFONIL AS NEW INHIBITORS OF HISTONE DEACETILASE.
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
TW200400960A (en) 2002-06-05 2004-01-16 Pharmacia Corp Novel pyrazoles and their use as P38 kinase inhibitors
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
PL1633724T3 (en) 2003-03-12 2011-10-31 Kudos Pharm Ltd Phthalazinone derivatives
HRP20080541T3 (en) * 2003-04-23 2008-12-31 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
FR2854158B1 (en) * 2003-04-25 2006-11-17 Sanofi Synthelabo 2-ACYLAMINO-4-PHENYLETHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
ATE370135T1 (en) 2003-07-18 2007-09-15 Glaxo Group Ltd SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS
JP2007531753A (en) * 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Non-imidazole heterocyclic compounds
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
WO2006012226A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
ES2573845T3 (en) 2004-06-25 2016-06-10 Janssen Pharmaceutica Nv CCR2 antagonists of quaternary salts
AU2005259983B2 (en) 2004-06-28 2011-07-28 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
KR20070057859A (en) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-heteroarylmethyl substituted phthalazinone derivatives
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
US7767677B2 (en) * 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
PA8653301A1 (en) * 2004-11-22 2006-11-09 Incyte Corp Incyte Corp SALTS OF THE N- [2 - ({(3R) -1- [TRANS-4-HIDROXI-4- (6-METOXIPIRIDIN-3-IL) CICLOHEXIL) PIRROLIDIN
DE102004061751A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidine-substituted pyrazolines
CA2589748C (en) * 2004-12-24 2013-08-13 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
US20080167322A1 (en) * 2005-02-16 2008-07-10 Pinkerton Anthony B Substituted Pyrazoles as Modulators of Chemokine Receptors
MX2007010076A (en) * 2005-02-17 2007-10-16 Astellas Pharma Inc Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative.
US20070032475A1 (en) * 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
JP2008545660A (en) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrropyridine compounds useful as protein kinase inhibitors
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
GB0517184D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
TWI329641B (en) 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
BRPI0616575A2 (en) 2005-09-27 2011-06-21 Irm Llc diarylamine-containing compounds and compositions, their use as c-kit receptor modulators as well as methods for their production
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Fast Dissociting Dopamine 2 Receptor Antagonists
WO2007053495A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20090062260A1 (en) 2005-11-14 2009-03-05 Irm Llc Compounds and compositions as lxr modulators
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
EP2465850B1 (en) 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Therapeutic compounds
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
AU2007238878A1 (en) 2006-04-11 2007-10-25 Merck Sharp & Dohme Corp. Diaryl substituted alkanes
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US20100168120A1 (en) 2006-04-28 2010-07-01 Neuromedix Inc. Salts of pyridazine compounds
DE602007004618D1 (en) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridine and pyrazine derivatives as MnK kinase inhibitors
MX347085B (en) * 2006-12-28 2017-04-06 Abbott Laboratories * Inhibitors of poly(adp-ribose)polymerase.
CA2676715A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP4785881B2 (en) 2007-02-27 2011-10-05 大塚製薬株式会社 Medicine
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
EA017392B1 (en) 2007-08-22 2012-12-28 Айрм Ллк 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
MX2010003621A (en) 2007-10-01 2010-04-14 Hoffmann La Roche New biaryl derivatives.
WO2009067406A1 (en) * 2007-11-20 2009-05-28 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
EP2225223B1 (en) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organic compounds
EP2062889A1 (en) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Compounds
CN102066359B (en) * 2008-06-18 2013-08-21 弗·哈夫曼-拉罗切有限公司 Novel heteroaryl carboxamide derivatives
BRPI0916576A2 (en) 2008-08-04 2017-06-27 Chdi Inc at least one chemical entity, pharmaceutical composition, and method for treating a condition or disorder.
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CA2735208A1 (en) * 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh Novel benzamides, production thereof, and use thereof as medicaments
ES2551557T3 (en) * 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammations, asthma and COPD
CA2750635A1 (en) * 2009-02-23 2010-08-26 Merck Canada Inc. Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2011073155A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
PL2513093T3 (en) * 2009-12-17 2015-03-31 Centrexion Therapeutics Corp New CCR2 receptor antagonists and their application
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) * 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
JP5721242B2 (en) * 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel CCR2 antagonist
WO2012171863A1 (en) 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
JP5786258B2 (en) * 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel and selective CCR2 antagonist

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032526A (en) * 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
WO1986006719A1 (en) * 1985-05-15 1986-11-20 Chemie Linz Aktiengesellschaft New pyridazine compositions, production process thereof and fungicides and algicides containing them
WO1999021834A1 (en) * 1997-10-27 1999-05-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
WO2003066604A2 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
WO2005009976A1 (en) * 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
US20050192302A1 (en) * 2003-12-18 2005-09-01 Chu-Biao Xue 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
WO2005084667A1 (en) * 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2006001958A2 (en) * 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
WO2006050389A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods
WO2007003604A2 (en) * 2005-07-04 2007-01-11 Novo Nordisk A/S Hists1mine h3 receptor antagonists
WO2007084868A2 (en) * 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1992, XP002461758, retrieved from STN Database accession no. 1992:571353 *
HU ET AL: "Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, 2007 - 17 October 2006 (2006-10-17), XP002459551, ISSN: 0960-894X *
ROWLEY M ET AL: "4-Heterocyclylpiperidines as Selective High-Affinity Ligands at the Human Dopamine D4 Receptor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, 1997, pages 2374 - 2385, XP002173936, ISSN: 0022-2623 *
XU PING ET AL: "Synthesis and anticonvulsant activity of 3-(substituted piperazino)-6-(substituted phenyl)pyridazines", BEIJING YIKE DAXUE XUEBAO, vol. 23, no. 6, 1991, pages 477-80 *

Also Published As

Publication number Publication date
AR066799A1 (en) 2009-09-16
JP2010528089A (en) 2010-08-19
JP5603770B2 (en) 2014-10-08
WO2008145681A2 (en) 2008-12-04
EP2155689B1 (en) 2015-07-08
US20100204209A1 (en) 2010-08-12
TW200904434A (en) 2009-02-01
US8653262B2 (en) 2014-02-18
CA2687931C (en) 2016-05-24
CA2687931A1 (en) 2008-12-04
EP2155689A2 (en) 2010-02-24
CL2008001593A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
MY160471A (en) New ccr2 receptor antagonists and uses thereof
EP1732917B8 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
IL186090A0 (en) Cgrp antagonists, method for the production thereof, and their use as medicaments
IL190423A0 (en) Selected cgrp antagonists , methods for the production thereof and their use as medicaments
WO2009061853A3 (en) Mutant interleukin-2 (il-2) polypeptides
WO2008045564A3 (en) Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
WO2008005345A3 (en) Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
IL180874A0 (en) Substituted, bicyclic 8-pyrrolidinoxanthines, method for the production thereof and their use as medicaments
WO2007122591A3 (en) Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
WO2007056470A3 (en) Neuropilin antagonists
WO2007027734A3 (en) Bicyclic and bridged nitrogen heterocycles
IL189497A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
WO2008020405A3 (en) Azetidine compounds as orexin receptor antagonists
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2006074428A3 (en) Cxcr4 antagonists for the treatment of medical disorders
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2008046581A3 (en) Substituted tetrahydropyrrolopyrazine compounds and use thereof in medicaments
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2011062437A3 (en) Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2006048248A3 (en) Novel anthranilamide pyridinureas as vegf receptor kinase imhibitors
WO2010077976A3 (en) Prokineticin receptor antagonists and uses thereof
IL185689A (en) Nk-i receptor antagonists, medicaments containing them, process for their preparation and uses thereof in the preparation of medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08760165

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2687931

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010509818

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008760165

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12602274

Country of ref document: US